So excited to see the gentle giant be recognized at #SGO 2025 annual meeting for contributions to the field particularly in rare ovarian tumors. John Farley also faithfully service our country as a colonel in the US military. Congratulations John! ⁦⁦@VaniamGroup⁩

Great session on PARPi in the current clinical climate. Patient-level decision algorithms will become more complicated and nuanced as Keylynk and FIRST report adding to data from DUO-O. Exciting options for patients #vaniam ⁦@ESGO_society⁩

Day 1 of #ESGO2025 Program filled with updates across the Gyn oncology spectrum. Always a great networking event with friends and colleagues in practice and industry with time to discuss and debate the clinical utility of the research findings. @VaniamGroup @GOG

This year’s SGO Winter Meeting brought exciting new research, insightful clinical trial reviews, and nuanced treatment strategies that are reshaping how we look at patient care. Integrating tumor biology into therapeutic advancements was particularly impactful. @vaniamgroup

Equally inspiring were the dynamic discussions with clinicians-in-training and the collaborative engagement with pharmaceutical partners, driving broader implementation of these breakthroughs. #FromTheDeskOfDr.RobColeman #OncologyInnovation #DigitalHealth #SGOWinterMeeting

Excited to see ROCC trial discussed at the winter SGO 2025 meeting. Thanks Dr Teoh for your discussion

Not my usual domain but excited to learn how novel therapies are being developed in other tumor types or under similar competitive treatment landscapes #ASH #vaniam

Two major events, one big goal: transforming lives through innovation. Counting down to #ash24 #sabcs

Celebrating Dr Ng and his tremendous work with our mentorship and training program. A huge success in bring expertise to many areas of the world with limited resources. We owe you and the team a huge debt of gratitude - thanks!

Congratulations Dr Cloven presenting quality of life data from the RUBY trial at #IGCS2024

Congratulations Shannon on updated results on DUO-E at #igcs2024

Happy to be at #IGCS2024 but with a solemn moment to remember our dear friends and patients who we lost

So finally we are at #IGCS 2024!! Love it! @IGCSociety @IJGCfellows @IJGConline @ESGO_society @SGO_org Looking forward to a great meeting! #Dublin @MethodistHosp

Incredibly moving and beautiful presentation by our good friend/colleague - dr Michael Frumovitz!!! #Physician/patient

#sgo congratulations to our sgo president ⁦@AngelesSecord⁩ for an amazing job!!!

Is selinexor the magic drug in NSMP endometrial cancer ? #esgo2024 An engaging discussion by Dr Sehouli

Congratulations prof fujiwara on an amazing conference and raising the tenor on the importance of palliative care for patients. Amazing presidential speaker Stephen Connor #igcs ⁦@IGCSociety⁩

#ASCO2023 wow- OS data confirms lasting benefit! New results from the MIRASOL trial. Congratulations Dr Moore. So rare to see PFS and OS Hazard Ratio of the same magnitude in gynecological cancer. #gyncsm

#ASCO2023 pfs in MIRASOL in PROC! HR: 0.65 is the true measure of clinical value -not the median! This is a 35% reduction in the probability of an event of progression or death - Not to be minimized nor misrepresented. Congratulations

Katy rocking it @ASCO MIRASOL demonstrates practice-changing data. This is the FIRST phase 3 trial of a novel agent to demonstrate OS in platinum resistant ovarian cancer. One of only a few phase 3 trials EVER to demonstrate OS in this clinical setting. Congrats to the team